Lorena Raquel Lerner - 24 Feb 2026 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Reporting relationship: Chief Scientific Officer
Issuer ticker: KROS
Reported as of: 24 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Feb 2026, 16:15:17 UTC
Prior SEC filing: 20 Feb 2026
Next SEC filing: 20 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Esther Cho, Attorney-in-Fact

Key filing fact

Lorena Raquel Lerner filed Form 4 for Keros Therapeutics, Inc. (KROS) on 26 Feb 2026.

Key facts

This page summarizes Lorena Raquel Lerner's Form 4 filing for Keros Therapeutics, Inc. (KROS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 Feb 2026, 16:15.

Change

Previous filing in this sequence was filed on 20 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002081359 Primary reporting owner

Lerner Lorena Raquel

Relationship: Chief Scientific Officer
Address: C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON
Signature: /s/ Esther Cho, Attorney-in-Fact
Signature date: 26 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KROS transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +75,000
Change %
Price: $0.000000
Shares after: 75,000
Date: 24 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 75,000
Exercise price: $15.52
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2027, and the remaining shares subject to the option shall vest in twelve substantially equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.